PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

telmisartan Side Effects

The reactions most often reported to the FDA for telmisartan (also sold as Micardis), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

33,611
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2001 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of telmisartan come from 33,611 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 33,611 reports to the FDA Adverse Event Reporting System (FAERS) for telmisartan (Micardis): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

33,611

Reports Mentioning Death

3,166

9.4% of reports — not proof the medicine caused the death

Hospitalizations

14,967

44.5% of reports

Top Indication

Hypertension

Most Reported Adverse Reactions

NAUSEA
2,059
FATIGUE
2,001
DIARRHOEA
1,794
DYSPNOEA
1,785
HEADACHE
1,715
DIZZINESS
1,682
FALL
1,594
BLOOD PRESSURE INCREASED
1,510
HYPERTENSION
1,460
ARTHRALGIA
1,428
MALAISE
1,424
ASTHENIA
1,408
VOMITING
1,353
PAIN
1,310
COUGH
1,234
PNEUMONIA
1,185
PYREXIA
1,180
PRURITUS
1,050

Who Reports Side Effects

Gender Distribution

Female 17,155 (56%)
Male 13,709 (44%)
Unknown 45

Age Distribution

0-17 293 (1%)
18-44 1,118 (5%)
45-64 7,409 (31%)
65-74 6,954 (29%)
75+ 7,961 (34%)

Reporting Trend by Year

2001 2025

Reactions in Death Reports

Top reactions reported in 3,166 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 660
SEPSIS 360
DIARRHOEA 340
DYSPNOEA 326
FALL 315
CARDIO-RESPIRATORY ARREST 312
DECREASED APPETITE 283
HAEMORRHAGIC STROKE 276
DIZZINESS 275
FATIGUE 268
ASTHENIA 267
HEADACHE 266
ALTERED STATE OF CONSCIOUSNESS 263
ASCITES 258
TACHYCARDIA 258
NAUSEA 255
ARTHRALGIA 254
PYREXIA 251
HAEMATEMESIS 249
PNEUMONIA 249

Reactions in Hospitalization Reports

Top reactions in 14,967 reports where hospitalization was an outcome.

Reaction Reports
FALL 1,015
PNEUMONIA 906
NAUSEA 892
DYSPNOEA 784
FATIGUE 777
VOMITING 774
PYREXIA 743
DIARRHOEA 700
MALAISE 684
ACUTE KIDNEY INJURY 678
ASTHENIA 663
PAIN 651
HYPOTENSION 641
HYPERTENSION 634
HEADACHE 609
BLOOD PRESSURE INCREASED 571
ANAEMIA 533
DIZZINESS 505

Compare telmisartan vs acebutolol →

What the FAERS Data Reveals About telmisartan Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 33,611 voluntary reports linked to telmisartan and its brand equivalents (Micardis), spanning 2001 through 2025. Of those, 3,166 (9.4%) listed death as an outcome and 14,967 (44.5%) involved hospitalization. The most common indication reported alongside adverse events was Hypertension.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 56% were female and 44% male; age distribution skews toward 75+, with 7,961 reports in that bracket. The single most reported reaction is nausea with 2,059 submissions, followed by fatigue and diarrhoea.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.